Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of nelarabine injection in relapsed or refractory T-ALL and T-LBL in children and adults
CTR20240655Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of nelarabine in Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL) and T-lymphoblastic lymphoma (T-LBL), sponsored by Nanjing Shunxin Pharmaceutical. Started May 2024; status: active.
02
Drugs
nelarabine
03
Conditions
Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on CTR20240655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240655.